IL-2 mutant fusion protein

Business news, market intelligence, and global industry analysis.

The Latest

Flint Development wins Spotsylvania County approval for Patriot 95 logistics facility in Thornburg, VA

Arbor Energy signs 5 GW deal with GridMarket to supply zero-emission baseload power from 2029

Representative image of a construction project manager using AI-driven risk analysis, cost forecasting, and anomaly detection tools as Acumatica 2026 R1 expands construction ERP capabilities to help contractors spot margin pressure earlier.

Acumatica 2026 R1 brings AI-driven project risk tools to construction ERP as margin pressure intensifies

Why NUBURU, Inc.’s Phase I activation with Maddox Defense matters for U.S. defense supply-chain resilience (NYSE American: BURU)

Simcere’s SIM0278 enters Phase II trial in China: Could IL-2 Treg fusion therapy transform atopic dermatitis care?

Simcere’s SIM0278 enters Phase II in China for atopic dermatitis. Explore how its IL-2 Treg selectivity could redefine treatment for autoimmune skin diseases.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

November 11, 2025